ATS 2024 Final Program

Click on the session title to view the speakers

123

MONDAY • MAY 20

10:05 The Odyssey of Lung Cancer Chemoprevention: It Came, It Went, and It Just May Come Back Again 10:25 We Can Cut Out More or Less; We Can Operate First or Last: The Flexibility of Thoracic Surgery in 2024 10:35 Summary: Lung Cancer Beyond 2024

approaches to screening and cessation that can be both applied broadly and individualized in diverse clinical settings. 9:15 Opening Remarks 9:20 Pharmacologic Treatment of Nicotine Dependence 9:40 Aftereffects of Vaping: An Adolescent Treatment Approach 10:00 Current Tobacco Policy and Regulation Updates 10:20 What’s Next After E-Cigarettes?: Cannabinoids, Including Dual Use 10:40 Closing Remarks B13 BREAKING NEWS: CLINICAL TRIAL RESULTS IN PULMONARY MEDICINE 9:15 a.m - 11:15 a.m. San Diego Convention Center Ballroom 20A (Upper Level) 9:15 Welcome and Introduction 9:25 A Randomized, Double-blind Trial of Amikacin Liposome Inhalation Suspension in Adults With Newly Diagnosed or Recurrent Mycobacterium Avium Complex Lung Disease to Validate Patient-reported Outcome Instruments and Assess Microbiological Outcomes of Treatment: The ARISE Study 9:40 Questions and Answers 9:50 Tezepelumab in Adults With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD): Efficacy and Safety From the Phase 2a COURSE Study 10:05 Questions and Answers 10:15Efficacy and Safety of Dupilumab in Patients With BEHAVIORAL • CLINICAL SCIENTIFIC SYMPOSIUM

BEHAVIORAL • CLINICAL SCIENTIFIC SYMPOSIUM

B12 QUITTING IS WINNING: TOBACCO AND E-CIGARETTE CESSATION Assemblies on Behavioral and Health Services Research; Environmental, Occupational and Population Health; Nursing; Pediatrics; Thoracic Oncology; Pediatric Advocacy Subcommittee; Tobacco Action Committee 9:15 a.m. - 10:45 a.m. San Diego Convention Center Room 2 (Upper Level) Target Audience Clinicians, trainees and multidisciplinary allied health personnel Objectives At the conclusion of this session, the participant will be able to: • describe the differences between various types of tobacco, nicotine, and vaping products and how this affects risk and nicotine dependence • appropriately evaluate and treat patients of all ages with nicotine dependence, utilizing both behavioral and pharmacologic interventions based on new guideline recommendations and best practices • improve the quality of care provided to those with nicotine dependence by understanding how to develop inpatient and outpatient treatment services The primary goal of this session is to provide a high-yield, evidence-based update on nicotine and e-cigarette use with a focus on screening and interventions. This session will cover the assessment and treatment of nicotine dependence, e-cigarette and vaping associated lung injury (EVALI) and its aftereffects, and the new and evolving area of cannabinoid vaping. The course will also include an up-to-date overview of current priorities of the FDA’s Center for Tobacco Products (CTP). Course faculty are multidisciplinary clinical, research, and advocacy experts. The session will cover the approach to both adolescent and adult patients, and will share evidence-based

Moderate-to-Severe COPD and Type 2 Inflammation: Phase 3 NOTUS Trial

10:30 Questions and Answers 10:40 TBD 10:55 Questions and Answers 11:05 Wrap-Up

ATS 2024 Conference Program • San Diego, CA